Blue Matter

Part 3 in our ongoing series on cell / gene therapies >> bit.ly/4uysKlh

NEW REPORT - Key Success Factors for a Best Practice Key Account Management Organization >> bit.ly/42pfB1H #pharmaceutical #biotech #KeyAccountManagement #biopharma #marketaccess

NEW REPORT - Key Success Factors for Building a Best Practice #PatientServices Organization >> bit.ly/41QvGNO #pharmaceutical #biotech #marketaccess #patientcentricity

Key Success Factors for Building a "Best Practice" US #MarketAccess Organization >> bit.ly/3QmYeMa #biotech #pharmaceuticals #organizationalexcellence

Blue Matter analysis of #biopharma deal activity during 2H2025 & what it means for 2026 & beyond >> bit.ly/4dKN7qh

Recently, our team attended the MAPS Americas meeting in Denver. Here are 5 key themes from the discussions there >> bit.ly/4sQKYOi #medicalaffairs #biotech #pharmaceutical

Often, revolutionary technologies make things worse before they make them better. Is that what #AI is doing in #biopharma R&D? >> bit.ly/3NK745Y #artificialintelligence #pharmaceuticals

4 key takeaways from the recent Informa #RareDisease Summit in Philadelphia >> bit.ly/4uS0P0t

What was once a relatively stable “buy-and-bill” ecosystem for physician-administered drugs is being significantly reshaped by a range of market and policy factors. Read our latest paper to learn more about them. bit.ly/4sArHkg

NEW: 5 key dynamics shaping the market for buy and bill drugs >> bit.ly/4bqu2H1

A look at the global #CDMO market & the opportunities, risks, & investment playbook for private equity >> bit.ly/4azkjyZ

10 Critical Success Factors for Launching & Commercializing Cell & Gene Therapies >> bit.ly/4aRvkvn #pharmaceutical #biotech #celltherapies #genetherapies #celltherapy #genetherapy

4 trends that will drive change in #RareDisease therapies in 2026 & beyond >> bit.ly/4abOH28 #RareDiseases #biotech #pharmaceuticals #biopharma

NEW >> 10 critical success factors for launching & commercializing cell / gene therapies >> bit.ly/4kvOwCk

#CNS market outlook for 2026 & beyond (biopharma R&D, commercialization) >> bit.ly/3O0BvEK

A look at opportunities, risks, and PE investment strategies in the global #CDMO market >> bit.ly/4cmICRP

It's time for our annual #oncology market outlook. Here are 7 key trends that will shape the market in 2026 & beyond >> bit.ly/4bykrzB

#CNS Market Outlook >> We identify 5 key trends that will shape the CNS market in 2026 >> bit.ly/3NXJMJq #biotech #pharmaceuticals #CentralNervousSystem #alzheimers #psychedelics

@ideapharma The image connotes a "balance" of RISK (on the top) and RETURN on the bottom (to which the RN belongs). Note how the blocks are balanced on their edges. Always more than one way to interpret an image.

@BlueMatter1 I know I'm being pedantic (competitor 😅), but the graphic is confusing me - return makes sense, but riskrn?

Most single-asset #biopharma companies will expand to build a portfolio of therapeutic assets. In this paper, we offer some insights regarding portfolio forecasting, prioritization, & management >> bit.ly/4kcqv2Y